Macquarie University, Sydney Macquarie University ResearchOnline

Showing items 1 - 13 of 13.

Add to Quick Collection   All 13 Results

  • First
  • Previous
  • 1
  • Next
  • Last
Sort:
 Add All Items to Quick Collection
Date: 2016
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1183579
Description: The anti-PD-1 antibodies nivolumab and pembrolizumab are active in metastatic melanoma; however, there is limited data on combining anti-PD-1 antibody and radiotherapy (RT). We sought to review clinic ... More
Reviewed: Reviewed
Date: 2016
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1111846
Description: 1 page(s)
Date: 2015
Subject Keyword: melanoma | BRAF | dabrafenib | trametinib | pyrexia | fever
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1059734
Description: Background: Pyrexia is a frequent adverse event with combined dabrafenib and trametinib therapy (CombiDT), but little is known of its clinical associations, etiology, or appropriate management. Patien ... More
Reviewed: Reviewed
Date: 2015
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1112545
Description: Background: BRAF inhibitors (BRAFi) cause paradoxical activation of the MAPK pathway in wild-type BRAF keratinocytes resulting in cutaneous squamous cell carcinoma (cuSCC). This study examined the fac ... More
Reviewed: Reviewed
Date: 2015
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1114219
Description: 1 page(s)
Date: 2015
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1047547
Description: Background: Ipilimumab (Yervoy; Bristol-Myers Squibb) is a novel fully humanised monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4, an immune checkpoint molecule, to augment anti-tumour ... More
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1110399
Description: background: The prognostic significance of BRAF and NRAS mutations in metastatic melanoma patients remains uncertain, with several studies reporting conflicting results, often biased by the inclusion ... More
Full Text: Full Text
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1114316
Description: Background: Anti-PD-1 therapy has demonstrated activity in MM however current data may not fully reflect patterns of response and relapse as discerned by comprehensive lesion-specific analysis. Method ... More
Reviewed: Reviewed
Date: 2013
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/294285
Description: Background:To examine the association between level and patterns of baseline intra-tumoural BRAF V600E protein expression and clinical outcome of BRAF V600E melanoma patients treated with selective BR ... More
Reviewed: Reviewed
Date: 2013
Subject Keyword: 110300 Clinical Sciences
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/293445
Description: Summary Background The treatment of metastatic melanoma has changed greatly with the development of inhibitors targeted at the mutated BRAF kinase present in up to 50% of metastatic melanoma cases. Th ... More
Reviewed: Reviewed
Date: 2012
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/294449
Description: Background Inhibitors of mutant BRAF are emerging as standard of care in patients with metastatic melanoma carrying relevant oncogenic mutations. Cutaneous reactions are frequent and significant. We c ... More
Reviewed: Reviewed
Date: 2011
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/294789
Description: The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy with cytotoxic drugs. New targeted agents directed against the RAS-RAF-MEK-ERK pathway show promising ... More
Reviewed: Reviewed
  • First
  • Previous
  • 1
  • Next
  • Last